Evidence map›Paper›PMID 16521187›Full record

ArticleWorld journal of gastroenterology2006

Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?

Androniki C Poulou, Konstantinos E Goumas, Dimitrios C Dandakis, Ioannis Tyrmpas, Maria Panagiotaki, Androniki Georgouli, Dimitrios C Soutos, Athanasios Archimandritis

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  6. Article
  7. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring.Pediatric nephrology (Berlin, Germany) · 2017
    Review
  8. Extraintestinal manifestations and complications in IBD.Nature reviews. Gastroenterology & hepatology · 2013
    Review
  9. Inflammatory bowel disease: Looking beyond the tract.International journal of immunopathology and pharmacology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Androniki C PoulouGastroenterology Department, Red Cross Hospital of Athens, Greece.
Konstantinos E Goumas
Dimitrios C Dandakis
Ioannis Tyrmpas
Maria Panagiotaki
Androniki Georgouli
Dimitrios C Soutos
Athanasios Archimandritis
Hellenic Red Cross · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate whether microproteinuria in patients with inflammatory bowel disease (IBD) is associated with the disease activity or the treatment with 5-aminosalicylic acid (5-ASA).

methodsWe prospectively studied microproteinuria in 86 consecutive patients with IBD, 61 with ulcerative colitis (UC) and 25 with Crohn's disease (CD), before as well as 2 and 6 months after their inclusion in the study. Forty-six patients received 5-ASA for a period of 28.8 months (range 1-168 mo). Microalbuminuria (mALB) and urine levels of the renal tubular proteins beta2-microglobulin (beta2mGLB) and beta-N-acetyl-D-glucosamidase (beta-NAG) as well as the creatinine clearance were determined in a 12-h overnight urine collection. Tumor necrosis factor-alpha (TNF-alpha) serum levels were also measured.

resultsA total of 277 measurements (194 in UC patients and 83 in CD patients) were performed. The prevalence of abnormal microproteinuria in UC and CD patients was 12.9% and 6.0% for mALB, 22.7% and 27.7% for beta2mGLB, and 11.3% and 8.4% for beta-NAG, respectively. mALB was not associated with IBD activity. Beta2mGLB and beta-NAG urine levels were correlated to UC activity (UCAI: P<0.01; UCEI: P<0.005). mALB in UC patients and beta-NAG urine levels in CD patients were related to TNF-alpha serum levels. An association was noticed between microproteinuria and smoking habit. Treatment with 5-ASA was not correlated to the severity of microproteinuria or to the changes of creatinine clearance.

conclusionMicroproteinuria is mainly associated with UC and its activity but not affected by 5-ASA.

Indexed as

AdolescentAdultAgedColitis, UlcerativeCreatinineCrohn DiseaseFemaleHumansInflammatory Bowel DiseasesMaleMesalamineMiddle AgedProspective StudiesProteinuriaCreatinineMesalamine

Identifiers

PMID16521187
PMCPMC4066124
OpenAlexW193604022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.